Lombardo D, Raimondi F
Servizio di Riabilitazione Cardiologica, Ospedale Cannizzaro, Catania, Italy.
J Cardiovasc Pharmacol. 1994;23 Suppl 5:S98-100. doi: 10.1097/00005344-199423005-00021.
Hypertension is well recognized to be an important cardiovascular risk factor and antihypertensive therapy has been shown to decrease cardiovascular mortality and morbidity as blood pressure control is achieved. At present, management of hypertension is obtained with effective compounds that exhibit a satisfactory safety profile. Among the antihypertensive drugs, calcium antagonists have been proven to possess this property. In the present study, our objective was to compare the antihypertensive effect of two new long-acting dihydropyridines, lacidipine and amlodipine, as once-daily monotherapies in mild-to-moderate hypertensive patients. Eighty hypertensive patients were recruited and after a 3-week washout period were randomized to receive lacidipine 4 mg once daily or amlodipine 10 mg once daily. After 4 weeks, hydrochlorothiazide 12.5 mg was added in patients not adequately controlled, and patients were treated for a total of 8 weeks. At this time, supine mean diastolic blood pressure decrease was 16 mm Hg in the lacidipine group and 10 mm Hg in the amlodipine group (p < = 0.01). Adverse events were reported in 28% of patients treated with lacidipine and in 48% of patients receiving amlodipine. Results of our pilot clinical experience show that lacidipine is a well-tolerated and effective compound, compared with amlodipine, in mild-to-moderate hypertensive patients.
高血压是公认的重要心血管危险因素，并且已表明抗高血压治疗可降低心血管死亡率和发病率，因为实现了血压控制。目前，高血压的管理是通过具有令人满意安全性的有效化合物来实现的。在抗高血压药物中，钙拮抗剂已被证明具有这一特性。在本研究中，我们的目的是比较两种新型长效二氢吡啶类药物拉西地平与氨氯地平在轻度至中度高血压患者中作为每日一次单一疗法的抗高血压效果。招募了80名高血压患者，经过3周的洗脱期后，随机分为每日一次接受4mg拉西地平或每日一次接受10mg氨氯地平治疗。4周后，对血压控制不佳的患者加用12.5mg氢氯噻嗪，患者总共接受8周治疗。此时，拉西地平组仰卧位平均舒张压下降16mmHg，氨氯地平组下降10mmHg（p<=0.01）。接受拉西地平治疗的患者中有28%报告了不良事件，接受氨氯地平治疗的患者中有48%报告了不良事件。我们的初步临床经验结果表明，在轻度至中度高血压患者中，与氨氯地平相比，拉西地平是一种耐受性良好且有效的化合物。
